We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Becton Dickinson and Company | NYSE:BDX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.395 | -0.17% | 234.605 | 235.52 | 233.73 | 235.00 | 1,354,464 | 20:13:25 |
From Nov 2023 to May 2024
By Will Feuer
Becton Dickinson said it has received 510(k) clearance from the U.S. Federal Drug Administration for its new blood-collection device that can obtain blood samples from a fingerstick that produce lab-quality results.
The device, called the BD MiniDraw Capillary Blood Collection System, is less invasive than traditional blood-collection methods and means that the blood can be drawn by a trained healthcare worker, instead of a specialized phlebotomist, BD said.
The company said the device also means that blood could be collected in more convenient locations, including retail pharmacies.
BD said the 510(k) clearances include blood collection for a lipid panel, certain chemistry tests, and hemoglobin and hematocrit testing, some of the most commonly ordered lab tests. BD also plans to expand the blood tests that can be enabled by the new device in the future.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
December 07, 2023 07:28 ET (12:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Becton Dickinson Chart |
1 Month Becton Dickinson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
